FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022851890> ?p ?o ?g. }

• W2022851890 endingPage "59" @default.
• W2022851890 startingPage "59" @default.
• W2022851890 abstract "Back to table of contents Previous article Next article Clinical & Research NewsFull AccessPopular Antianxiety Herb Linked to Liver DamageJim RosackJim RosackSearch for more papers by this authorPublished Online:19 Apr 2002https://doi.org/10.1176/pn.37.8.0059The U.S. Food and Drug Administration is joining authorities in Canada and the European Union in an investigation of the popular herbal supplement kava (also known as kava kava or Piper methysticum). The herb is promoted to relieve stress, anxiety, and insomnia, as well as premenstrual symptoms.European officials have received about 25 reports of moderate-to-severe liver toxicity, and the FDA has logged 38 similar reports, including liver damage severe enough to require transplant and at least one case leading to death.The Canadian government has urged consumers not to take kava, while sales have been suspended in Switzerland and Great Britain. Germany is moving the herb from over-the-counter availability to requiring a prescription.In the United States, the National Institutes of Health has suspended two clinical studies of the herb, and the FDA is urging clinicians to look for any connection to the herb in patients with liver failure.So far, the FDA’s inquiry has turned up some startling findings about how Americans use the unregulated supplement. According to FDA officials, many people believe that “as a natural herb, it is perfectly harmless. It is anything but.” The agency officials, commenting in a press release announcing the investigation, asked physicians across the country to review files of patients with liver toxicity to determine whether there was any connection with the herb and to question patients who present with new signs of liver failure about use of herbal supplements.Christine Lewis Taylor, Ph.D., director of the FDA’s Office of Nutritional Products, Labeling, and Dietary Supplements, cited the cases of two 13-year-olds who were hospitalized after liver failure suspected of being caused by kava and a women who suffered both kidney and liver failure after taking in excess of 20 kava tablets a day. Another case of severe liver failure involved a woman who took up to 15 kava supplement pills a day, in addition to fluoxetine and other prescription drugs.In a “dear doctor” letter issued February 12, Taylor urged physicians to report “any cases of hepatic toxicity that you think may be related to the use of kava-containing dietary supplements.”Adverse events should be reported to the FDA’s MedWatch program at (800) 332-1088 or on the Web at www.fda.gov/medwatch. ▪ ISSUES NewArchived" @default.
• W2022851890 created "2016-06-24" @default.
• W2022851890 creator A5008516072 @default.
• W2022851890 date "2002-04-19" @default.
• W2022851890 modified "2023-09-26" @default.
• W2022851890 title "Popular Antianxiety Herb Linked to Liver Damage" @default.
• W2022851890 doi "https://doi.org/10.1176/pn.37.8.0059" @default.
• W2022851890 hasPublicationYear "2002" @default.
• W2022851890 type Work @default.
• W2022851890 sameAs 2022851890 @default.
• W2022851890 citedByCount "1" @default.
• W2022851890 crossrefType "journal-article" @default.
• W2022851890 hasAuthorship W2022851890A5008516072 @default.
• W2022851890 hasConcept C108170787 @default.
• W2022851890 hasConcept C111472728 @default.
• W2022851890 hasConcept C126322002 @default.
• W2022851890 hasConcept C138885662 @default.
• W2022851890 hasConcept C2776910463 @default.
• W2022851890 hasConcept C2778137410 @default.
• W2022851890 hasConcept C2779824472 @default.
• W2022851890 hasConcept C29730261 @default.
• W2022851890 hasConcept C2991655182 @default.
• W2022851890 hasConcept C2993709057 @default.
• W2022851890 hasConcept C41895202 @default.
• W2022851890 hasConcept C556039675 @default.
• W2022851890 hasConcept C71924100 @default.
• W2022851890 hasConceptScore W2022851890C108170787 @default.
• W2022851890 hasConceptScore W2022851890C111472728 @default.
• W2022851890 hasConceptScore W2022851890C126322002 @default.
• W2022851890 hasConceptScore W2022851890C138885662 @default.
• W2022851890 hasConceptScore W2022851890C2776910463 @default.
• W2022851890 hasConceptScore W2022851890C2778137410 @default.
• W2022851890 hasConceptScore W2022851890C2779824472 @default.
• W2022851890 hasConceptScore W2022851890C29730261 @default.
• W2022851890 hasConceptScore W2022851890C2991655182 @default.
• W2022851890 hasConceptScore W2022851890C2993709057 @default.
• W2022851890 hasConceptScore W2022851890C41895202 @default.
• W2022851890 hasConceptScore W2022851890C556039675 @default.
• W2022851890 hasConceptScore W2022851890C71924100 @default.
• W2022851890 hasIssue "8" @default.
• W2022851890 hasLocation W20228518901 @default.
• W2022851890 hasOpenAccess W2022851890 @default.
• W2022851890 hasPrimaryLocation W20228518901 @default.
• W2022851890 hasRelatedWork W1525983371 @default.
• W2022851890 hasRelatedWork W1546503587 @default.
• W2022851890 hasRelatedWork W1562530724 @default.
• W2022851890 hasRelatedWork W1983828382 @default.
• W2022851890 hasRelatedWork W2027706303 @default.
• W2022851890 hasRelatedWork W2371685590 @default.
• W2022851890 hasRelatedWork W2391594582 @default.
• W2022851890 hasRelatedWork W2393610146 @default.
• W2022851890 hasRelatedWork W2775971147 @default.
• W2022851890 hasRelatedWork W2797752772 @default.
• W2022851890 hasVolume "37" @default.
• W2022851890 isParatext "false" @default.
• W2022851890 isRetracted "false" @default.
• W2022851890 magId "2022851890" @default.
• W2022851890 workType "article" @default.